Mark Tyo
Family · Hyannis, MANPI 1386359420
Payments from drug & device makers
Across 152 payments — averaging $23.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tolmar, Inc.$514
- Sumitomo Pharma America, Inc.$429
- Accord Healthcare, Inc.$326
- Endo USA, Inc.$285
- Ferring Pharmaceuticals Inc.$273
- Urogen Pharma, Inc.$258
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,514100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tolmar, Inc. | 28 | $514 |
| Sumitomo Pharma America, Inc. | 20 | $429 |
| Accord Healthcare, Inc. | 13 | $326 |
| Endo USA, Inc. | 10 | $285 |
| Ferring Pharmaceuticals Inc. | 13 | $273 |
| Urogen Pharma, Inc. | 7 | $258 |
| 180 Medical, Inc. | 9 | $234 |
| Antares Pharma, Inc. | 8 | $183 |
| AbbVie | 7 | $156 |
| Johnson & Johnson | 4 | $122 |
| Endo Pharmaceuticals Inc. | 5 | $120 |
| Immunitybio, Inc. | 5 | $111 |
| Myriad Genetic Laboratories, Inc. | 4 | $83 |
| BD | 3 | $80 |
| Progenics Pharmaceuticals, Inc. | 3 | $56 |
| Bayer | 2 | $50 |
| Convatec Inc. | 1 | $46 |
| Halozyme Inc | 2 | $46 |
| Boston Scientific | 2 | $43 |
| Coloplast | 2 | $37 |
| Telix Pharmaceuticals | 1 | $21 |
| Medtronic | 1 | $16 |
| Procept Biorobotics Corporation | 1 | $16 |
| Teleflex LLC | 1 | $14 |
How this compares
$3,519 in reported general payments places this provider in the 90th percentile of 2,320 family providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 52 | $51,763 |
| XyostedTestosterone Enanthate | 32 | $26,580 |
| MyrbetriqMirabegron | 28 | $20,038 |
| Testosterone | 119 | $18,821 |
| Methenamine Hippurate | 135 | $9,599 |
| Tamsulosin Hcl | 375 | $6,702 |
| Testosterone Cypionate | 234 | $4,864 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 134 | $3,174 |
| Oxybutynin Chloride ErOxybutynin Chloride | 66 | $2,283 |
| Finasteride | 130 | $2,216 |
| Cefpodoxime Proxetil | 35 | $2,169 |
| Desmopressin Acetate | 21 | $1,859 |
| Solifenacin Succinate | 29 | $1,672 |
| Trospium Chloride | 22 | $1,575 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 61 | $1,110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $429 | $51,76352 claims |
| Antares Pharma, Inc.Xyosted | $183 | $26,58032 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,320 family providers in Massachusetts.
Other family in Hyannis
- Carrie SullivanHyannis$7K
- Paul GouldLakeville$343K
- Brittany MurrayBoston$141K
- Courtney NixonAmherst$81K
- Elizabeth WalshBrighton$80K
- Jennifer FlemingLawrence$80K
- Naomi AmudalaBoston$79K
- Geoffrey WhitleyCharlestown$66K
- Katherine O'BrienWinthrop$58K
- Kristy SmithActon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.